HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2023 FINANCIAL RESULTS ON OCTOBER 31, 2023

PLYMOUTH MEETING, Pa., Oct. 17, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will report third quarter 2023 financial results on Tuesday, October 31, 2023, before the open of the U.S. financial markets. Harmony will host a conference call and live webcast on October 31, 2023, at 8:30 a.m. ET to discuss the results.

To participate in the call, please dial [phone] (domestic) or [phone] (international), and reference passcode HRMYQ323. It is recommended that you dial in at least 10 minutes prior to the call.

The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/.

About Harmony Biosciences
At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for our patients, who are at the heart of everything we do. For more information, please visit www.harmonybiosciences.com.

Harmony Biosciences Investor Contact:
Luis Sanay, CFA
445-235-8386
[e-mail]

Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
[e-mail]

View original content to download multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-to-report-third-quarter-2023-financial-results-on-october-31-2023-301957939.html

SOURCE Harmony Biosciences

Copyright 2023 PR Newswire